Teva v. Amneal: Device Patents Do Not Belong in the Orange Book

Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, 124 F.4th 898 (Fed. Cir. 2024), No. 24-1936, decided December 20, 2024, is the decision that ended the practice of listing pure device patents in the FDA Orange Book. The Federal Circuit affirmed an order requiring Teva to delist patents that claimed only the hardware of its ProAir HFA metered-dose inhaler, such as the dose counter, while claiming nothing about albuterol sulfate, the active ingredient in the approved product. The ruling reshapes the strategic map for inhalers, injectors, and other drug-device combinations, and it arrived with the Federal Trade Commission, an amicus on Amneal’s side, cheering the outcome.

At a glance

• Case: Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, 124 F.4th 898 (Fed. Cir. 2024), No. 24-1936
• Decided: December 20, 2024; Federal Circuit, affirming the U.S. District Court for the District of New Jersey
• Holding: A patent is eligible for Orange Book listing only if it claims the drug for which the new drug application was submitted, which requires claiming the active ingredient; patents claiming only device components of the approved product must be delisted
• Panel: Prost (author), Taranto, Hughes
• Status: The Federal Circuit denied rehearing en banc on March 3, 2025. The Chief Justice extended Teva’s certiorari deadline to July 31, 2025, but no petition appears on the Supreme Court’s docket. The delisting order stands as of July 2026

The Orange Book and the listing statute

The Orange Book, formally Approved Drug Products with Therapeutic Equivalence Evaluations, is the FDA’s public register of approved drugs and the patents that brand manufacturers certify cover them. Listing is not a mere clerical act. Under the Hatch-Waxman framework, a brand holder of a new drug application (NDA) must submit for listing each patent that claims the approved drug or a method of using it, per 21 U.S.C. § 355(b)(1) and (c)(2). A generic applicant filing an abbreviated new drug application must then address each listed patent, and a paragraph IV certification that a listed patent is invalid or not infringed can trigger an automatic 30-month stay of FDA approval. The listing decision therefore carries enormous competitive weight: what goes in the book can delay a generic for years.

That leverage is precisely why the scope of the listing obligation matters. If a brand can list patents that claim only the plastic and metal of a delivery device, it can multiply the certifications a generic must make and multiply the litigation and stays that follow, even where nothing about the actual drug is patented.

The dispute: inhaler hardware in the book

Teva markets ProAir HFA, an albuterol sulfate metered-dose inhaler approved under an NDA. Teva lists nine non-expired patents in the Orange Book for ProAir HFA. Five were at issue here, the ones Teva asserted against Amneal, and each claimed features of the inhaler device itself, including the dose counter and canister structure. It was undisputed that no claim in any of those five patents recites albuterol sulfate, or indeed any active ingredient at all.

Amneal sought to market a generic version and filed a paragraph IV certification. It then counterclaimed under the delisting provision of the statute, contending the device patents did not properly claim the drug and had to be removed. On June 10, 2024 the district court agreed and granted Amneal judgment on the pleadings, ordering delisting on the ground that the inhaler patents contain no claim for albuterol sulfate and instead are directed to components of a metered inhaler device. Teva appealed, and the Federal Circuit stayed the delisting order pending its resolution of the case.

The court’s reasoning: claim the drug, not the container

The Federal Circuit lifted its stay and affirmed. Its analysis turned on the statutory text that conditions listing on a patent that “claims the drug.” The court read “the drug” to mean the drug for which the applicant submitted the NDA, and it held that a patent claims that drug only if the patent claims the active ingredient. A patent that recites an inhaler, a dose counter, or a canister, without claiming the active ingredient, does not claim the drug; it claims a device that happens to deliver the drug.

The court rejected Teva’s broader reading that any patent claiming the approved product as a whole, integrated device included, satisfies the statute. That construction, the court reasoned, would sweep in patents on components untethered from the therapeutic agent and would let brand holders convert ordinary device patents into Orange Book listings and their attendant stays. The statute’s structure and evident purpose, channeling the paragraph IV process toward patents that actually cover the drug, foreclosed that outcome. Because Teva’s five device patents did not claim albuterol sulfate, they failed the listing requirement and had to be delisted.

The court was careful to describe the consequence as a listing question, not a validity or infringement question. Delisting removes a patent from the Orange Book and its paragraph IV apparatus; it does not extinguish the patent or the owner’s right to sue an infringer in an ordinary action. That distinction matters because it locates the holding squarely within the Hatch-Waxman listing scheme rather than in substantive patent law, and it explains why the remedy the district court fashioned was an order to correct the register rather than a judgment about the merits of the device patents themselves.

The Federal Trade Commission, which had campaigned against device-patent Orange Book listings as a driver of anticompetitive delay, was not a bystander: it filed amicus briefs in both the district court and the Federal Circuit urging delisting, and it had separately challenged Teva’s inhaler patents through the FDA’s Orange Book dispute process. On the day of the decision, Hannah Garden-Monheit, Director of the FTC’s Office of Policy Planning, said the Commission was “pleased the court agreed with the FTC that these improper inhaler patent listings must be wiped from the Orange Book,” adding that removing “junk patent listings” is critical to letting drugmakers compete to offer generics at lower prices.

What the decision changed

Before Teva v. Amneal, brand manufacturers routinely listed device and combination-product patents to fortify their Orange Book positions. After it, the listing test is sharper and narrower: no claim to the active ingredient, no listing. The ruling does not invalidate the device patents or bar Teva from enforcing them in a conventional infringement action. It removes only their Orange Book status and the paragraph IV leverage that status confers. For drug-device combinations, which dominate respiratory and injectable therapeutics, the decision forces a reassessment of which patents can anchor Hatch-Waxman litigation and which cannot.

Open questions

The opinion draws a clean line around the pure device patent, but combination products live in the gray zone between hardware and chemistry. How should a patent be treated when its claims recite the active ingredient together with device elements, an integrated formulation-in-device claim rather than a bare dose counter? Teva v. Amneal signals that a genuine claim to the active ingredient can support listing, but the precise mix of drug and device language that qualifies will be tested case by case. The decision also leaves open the remedial and damages consequences of past improper listings, including whether antitrust or unfair-competition exposure follows from listings later found improper, a theory the FTC has pressed independently. Finally, the interaction with biologics, which are governed by a separate framework without an Orange Book, remains outside the holding but not outside the strategic conversation.

Implications for inventors and businesses

• Audit Orange Book listings against the active-ingredient test. Delist or decline to list patents that claim only device hardware. An improper listing now invites a delisting counterclaim and possible regulatory scrutiny.
• Draft combination-product claims deliberately. If Orange Book eligibility matters, ensure the patent genuinely claims the active ingredient, not just the delivery apparatus. Separate pure device claims into patents whose value you will realize through ordinary infringement enforcement.
• Recalibrate life-cycle strategy for inhalers and injectors. Device-patent thickets can no longer generate paragraph IV stays. Plan generic-defense timelines around patents that actually cover the drug.
• Expect FTC attention. The Commission treats overbroad listings as competition harms. Listing decisions should be made with an eye to antitrust as well as patent strategy.

Frequently asked questions

What did Teva v. Amneal decide about Orange Book listings? The Federal Circuit held that to be properly listed in the FDA Orange Book, a patent must claim the drug for which the applicant submitted its new drug application, and that means claiming the active ingredient. Patents claiming only device components of the approved product do not qualify and must be delisted.

Why does an improper Orange Book listing matter to competitors? Listing a patent triggers the paragraph IV certification and 30-month stay machinery of Hatch-Waxman, delaying generic entry. Overbroad device-patent listings can block or slow lower-cost competition, which is why the FTC backed delisting as an anticompetitive-practices concern.

Does Teva v. Amneal ban all patents on drug-device combination products? No. It does not invalidate device patents or bar their enforcement in ordinary infringement suits. It holds only that a patent must claim the drug’s active ingredient to be eligible for Orange Book listing, so pure device patents cannot ride the Orange Book’s litigation advantages.

Authorities and sources

• Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, 124 F.4th 898 (Fed. Cir. 2024), No. 24-1936 (Dec. 20, 2024), slip opinion (U.S. Court of Appeals for the Federal Circuit).
• 21 U.S.C. § 355, especially § 355(b)(1) and (c)(2) (Orange Book listing) and § 355(j)(5)(C)(ii)(I) (delisting counterclaim), Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman).
• FTC Statement on the delisting decision.
• Cooley client alert and Crowell & Moring, “Only Drugs Allowed”.
• Patently-O, “Orange Book Device Patent Listings: Understanding Teva v. Amneal” and DLA Piper analysis.